DOI 10.1038/s41391-025-01049-5
Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer.
Аннотация
BACKGROUND
Abiraterone acetate/prednisone (AAP) plus a luteinizing hormone releasing hormone agonist or antagonist (LHRH-A) is commonly used for treating high risk M0 or oligometastatic prostate cancer, but prolonged LHRH-A can be associated with delayed and incomplete testosterone (T) recovery after discontinuation.
METHODS
We assessed impact of earlier LHRH-A discontinuation prior to stopping AAP on testosterone recovery (TR) to ≥150 ng/dl in an institutional cohort of patients who received 500-800 days of treatment.
RESULTS
100% (89/89) had testosterone <20 ng/dl at AAP end of treatment, and discontinuing LHRH-A ≥ 12 months prior to stopping AAP demonstrated improvement in 6-month TR (76.9%, 95% CI 39.7-92.8) compared to <3 months prior to stopping AAP (13.0%, 95% CI 4.7-25.8; HR 0.27[0.11-0.66], p < 0.01).
CONCLUSIONS
Early LHRH-A discontinuation 12 months or more prior to stopping AAP is associated with faster and more frequent T recovery compared to LHRH-A discontinuation within 3 months of AAP cessation, with T levels remaining appropriately suppressed during abiraterone monotherapy.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.